Medicinal BPC-157

every coordinate, sourced

The BPC-157 Reference Record

Every quantitative claim on this site resolves to one of the entries below — the primary BPC-157 studies, the 2024-2026 literature, and the FDA and WADA regulatory sources.

Back to the researchRecent research

About this reference list

This is the full BPC-157 reference list for the site. Entries 1-7 are the foundational and mechanistic primary studies; entries 8-15 and 17 are the 2024-2026 reviews and human pilots that the recent-research page draws on; entries 16, 18, and 19 are the regulatory sources behind the legal-status page. Where a study reports a number used elsewhere on this site — a dose, a half-life, an inhibition ratio — that number is tied to its entry here. DOIs, PubMed identifiers, and URLs are listed so each claim can be checked against its source.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
  3. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
  4. Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. ↗
  5. Recovery of the definitive and early spinal cord injury by the application of pentadecapeptide BPC 157 therapy. Curr Issues Mol Biol. 2022;44(5):1901-1927. ↗
  6. Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation in mice. Life Sci. 2022;310:121072. ↗
  7. Stable gastric pentadecapeptide BPC 157 - possible novel therapy of glaucoma and other ocular conditions. Pharmaceuticals (Basel). 2023;16(7):1052. ↗
  8. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025. ↗
  9. McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025. ↗
  10. Stable gastric pentadecapeptide BPC 157 and intestinal anastomoses therapy in rats - a review. Pharmaceuticals (Basel). 2024;17(8):1081. ↗
  11. Multifunctionality and possible medical application of the BPC 157 peptide - literature and patent review. Pharmaceuticals (Basel). 2025;18(2):185. ↗
  12. Protective effects of BPC 157 on liver, kidney, and lung distant organ damage in rats with acute pancreatitis. Medicina (Kaunas). 2025;61(2):291. ↗
  13. Stable gastric pentadecapeptide BPC 157 as a therapy and safety key: a special beneficial effect following intoxications. Pharmaceuticals (Basel). 2025;18(6):928. ↗
  14. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing (human-data and investigational-status assessment). Curr Rev Musculoskelet Med. 2025. ↗
  15. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant. Inflammopharmacology. 2025. ↗
  16. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (BPC-157 free base / BPC-157 acetate, Category 2; effective 2023-09-29) and Bulk drug substances used in compounding under section 503A of the FD&C Act. ↗
  17. From regeneration to analgesia: the role of BPC-157 in tissue repair and pain management. Int J Mol Sci. 2026. ↗
  18. World Anti-Doping Agency. The Prohibited List - S0 Non-Approved Substances (BPC-157 prohibited in sport at all times). ↗
  19. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (BPC-157, KPV, TB-500, and MOTs-C listed as substances being considered for inclusion on the 503A Bulks List). ↗